| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Congenital Abnormalities | 27 | 2025 | 249 | 8.960 |
Why?
|
| Rhabdomyosarcoma | 21 | 2025 | 200 | 7.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 42 | 2024 | 805 | 5.890 |
Why?
|
| Neoplasms | 30 | 2024 | 2758 | 5.220 |
Why?
|
| Maternal Exposure | 31 | 2020 | 148 | 5.210 |
Why?
|
| Registries | 44 | 2025 | 1394 | 5.080 |
Why?
|
| Air Pollutants | 15 | 2019 | 101 | 4.620 |
Why?
|
| Genetic Predisposition to Disease | 41 | 2024 | 3084 | 3.500 |
Why?
|
| Child | 148 | 2025 | 24241 | 3.240 |
Why?
|
| Texas | 60 | 2024 | 3560 | 3.220 |
Why?
|
| Infant | 97 | 2025 | 12350 | 3.050 |
Why?
|
| Neural Tube Defects | 13 | 2023 | 351 | 3.040 |
Why?
|
| Cancer Survivors | 13 | 2024 | 199 | 2.970 |
Why?
|
| Polymorphism, Single Nucleotide | 33 | 2024 | 2586 | 2.960 |
Why?
|
| Cleft Palate | 9 | 2022 | 140 | 2.950 |
Why?
|
| Central Nervous System Neoplasms | 10 | 2023 | 194 | 2.940 |
Why?
|
| Humans | 288 | 2025 | 123224 | 2.570 |
Why?
|
| Female | 204 | 2025 | 65550 | 2.530 |
Why?
|
| Environmental Exposure | 12 | 2024 | 217 | 2.470 |
Why?
|
| Infant, Newborn | 73 | 2025 | 8108 | 2.440 |
Why?
|
| Genome-Wide Association Study | 26 | 2024 | 1642 | 2.430 |
Why?
|
| Risk Factors | 80 | 2025 | 10015 | 2.370 |
Why?
|
| Case-Control Studies | 55 | 2024 | 3249 | 2.330 |
Why?
|
| Kidney Neoplasms | 5 | 2025 | 432 | 2.310 |
Why?
|
| Cleft Lip | 7 | 2022 | 124 | 2.290 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2024 | 532 | 2.290 |
Why?
|
| Vehicle Emissions | 5 | 2019 | 19 | 2.250 |
Why?
|
| Male | 173 | 2025 | 60118 | 2.230 |
Why?
|
| Folic Acid | 15 | 2024 | 292 | 2.200 |
Why?
|
| Leukemia | 6 | 2023 | 375 | 2.200 |
Why?
|
| Heart Defects, Congenital | 25 | 2024 | 1806 | 2.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 12 | 2021 | 228 | 2.160 |
Why?
|
| Adolescent | 94 | 2025 | 19110 | 2.100 |
Why?
|
| Pregnancy | 62 | 2023 | 7161 | 2.090 |
Why?
|
| Child, Preschool | 80 | 2025 | 13888 | 2.080 |
Why?
|
| DNA Methylation | 14 | 2024 | 988 | 2.030 |
Why?
|
| Hypospadias | 7 | 2022 | 81 | 2.010 |
Why?
|
| Residence Characteristics | 8 | 2024 | 269 | 2.010 |
Why?
|
| Young Adult | 71 | 2025 | 8865 | 1.940 |
Why?
|
| Wilms Tumor | 3 | 2025 | 111 | 1.870 |
Why?
|
| Anophthalmos | 5 | 2024 | 24 | 1.860 |
Why?
|
| Adult | 102 | 2024 | 29072 | 1.850 |
Why?
|
| Microphthalmos | 5 | 2024 | 60 | 1.840 |
Why?
|
| Prevalence | 35 | 2024 | 2406 | 1.820 |
Why?
|
| Congenital Microtia | 3 | 2022 | 16 | 1.810 |
Why?
|
| Neuroblastoma | 6 | 2024 | 509 | 1.760 |
Why?
|
| Benzene | 7 | 2015 | 24 | 1.650 |
Why?
|
| Birth Weight | 7 | 2023 | 336 | 1.630 |
Why?
|
| Down Syndrome | 10 | 2023 | 195 | 1.630 |
Why?
|
| Medulloblastoma | 8 | 2022 | 338 | 1.630 |
Why?
|
| Premature Birth | 7 | 2023 | 380 | 1.580 |
Why?
|
| Neoplasms, Second Primary | 3 | 2024 | 151 | 1.540 |
Why?
|
| Diabetes, Gestational | 3 | 2022 | 109 | 1.520 |
Why?
|
| Occupational Exposure | 11 | 2020 | 129 | 1.510 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 8 | 2020 | 67 | 1.480 |
Why?
|
| Air Pollution | 6 | 2024 | 67 | 1.470 |
Why?
|
| Abnormalities, Multiple | 6 | 2022 | 964 | 1.380 |
Why?
|
| Hepatoblastoma | 5 | 2024 | 178 | 1.380 |
Why?
|
| Incidence | 25 | 2025 | 3048 | 1.380 |
Why?
|
| Maternal Age | 10 | 2023 | 137 | 1.380 |
Why?
|
| Coloboma | 3 | 2024 | 45 | 1.350 |
Why?
|
| Liver Neoplasms | 7 | 2025 | 1309 | 1.350 |
Why?
|
| Neonatal Screening | 6 | 2024 | 184 | 1.330 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 4 | 2023 | 37 | 1.310 |
Why?
|
| United States | 50 | 2025 | 10637 | 1.310 |
Why?
|
| Metabolomics | 4 | 2021 | 409 | 1.290 |
Why?
|
| Logistic Models | 24 | 2023 | 1793 | 1.270 |
Why?
|
| Gastroschisis | 6 | 2020 | 53 | 1.260 |
Why?
|
| Cerebellar Neoplasms | 6 | 2022 | 282 | 1.250 |
Why?
|
| Odds Ratio | 25 | 2024 | 1243 | 1.230 |
Why?
|
| Lymphoma | 3 | 2023 | 321 | 1.230 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 4 | 2023 | 51 | 1.220 |
Why?
|
| Sarcoma | 3 | 2019 | 194 | 1.210 |
Why?
|
| Spinal Dysraphism | 10 | 2018 | 265 | 1.190 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 293 | 1.180 |
Why?
|
| Histiocytosis, Langerhans-Cell | 7 | 2024 | 221 | 1.160 |
Why?
|
| Population Surveillance | 12 | 2023 | 386 | 1.140 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2024 | 78 | 1.110 |
Why?
|
| Gene-Environment Interaction | 5 | 2019 | 120 | 1.080 |
Why?
|
| Craniosynostoses | 3 | 2020 | 131 | 1.070 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2021 | 123 | 1.060 |
Why?
|
| Exome | 5 | 2023 | 1041 | 1.060 |
Why?
|
| Hazardous Substances | 4 | 2021 | 17 | 1.060 |
Why?
|
| Live Birth | 10 | 2024 | 55 | 1.050 |
Why?
|
| Biliary Atresia | 7 | 2023 | 186 | 1.040 |
Why?
|
| Genotype | 22 | 2024 | 2542 | 1.030 |
Why?
|
| Sarcoma, Ewing | 2 | 2024 | 116 | 1.010 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2019 | 485 | 0.990 |
Why?
|
| Bone Neoplasms | 4 | 2025 | 429 | 0.980 |
Why?
|
| Atrazine | 3 | 2013 | 5 | 0.980 |
Why?
|
| Biomarkers, Tumor | 3 | 2025 | 1438 | 0.970 |
Why?
|
| Herbicides | 3 | 2013 | 11 | 0.970 |
Why?
|
| Particulate Matter | 4 | 2024 | 69 | 0.910 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 667 | 0.900 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2023 | 16 | 0.880 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 1118 | 0.880 |
Why?
|
| Thyroid Neoplasms | 3 | 2025 | 197 | 0.870 |
Why?
|
| Osteosarcoma | 2 | 2023 | 257 | 0.870 |
Why?
|
| Population Dynamics | 2 | 2015 | 29 | 0.850 |
Why?
|
| Choanal Atresia | 2 | 2012 | 18 | 0.830 |
Why?
|
| Turner Syndrome | 1 | 2023 | 47 | 0.820 |
Why?
|
| Thyroxine | 2 | 2012 | 65 | 0.820 |
Why?
|
| Metabolic Networks and Pathways | 3 | 2019 | 184 | 0.800 |
Why?
|
| Fertilization in Vitro | 2 | 2021 | 189 | 0.790 |
Why?
|
| Pregnancy Complications | 7 | 2022 | 507 | 0.780 |
Why?
|
| Aortic Coarctation | 1 | 2023 | 105 | 0.770 |
Why?
|
| Obesity | 7 | 2020 | 2226 | 0.760 |
Why?
|
| Infertility | 1 | 2022 | 90 | 0.750 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2021 | 41 | 0.740 |
Why?
|
| Bone Marrow | 3 | 2021 | 323 | 0.730 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 1306 | 0.720 |
Why?
|
| Metabolome | 2 | 2021 | 292 | 0.720 |
Why?
|
| Methotrexate | 6 | 2024 | 341 | 0.710 |
Why?
|
| Neuroectodermal Tumors, Primitive | 3 | 2022 | 52 | 0.710 |
Why?
|
| Brain Neoplasms | 5 | 2023 | 1236 | 0.700 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 849 | 0.700 |
Why?
|
| Mothers | 9 | 2023 | 350 | 0.690 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 121 | 0.680 |
Why?
|
| Germ Cells | 5 | 2024 | 192 | 0.670 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 42 | 0.660 |
Why?
|
| Digestive System Abnormalities | 1 | 2019 | 32 | 0.660 |
Why?
|
| Emigrants and Immigrants | 1 | 2021 | 147 | 0.660 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2021 | 169 | 0.660 |
Why?
|
| Air Pollution, Indoor | 2 | 2019 | 30 | 0.650 |
Why?
|
| Sarcoma, Synovial | 3 | 2024 | 21 | 0.650 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.650 |
Why?
|
| Butadienes | 2 | 2015 | 19 | 0.640 |
Why?
|
| Radon | 2 | 2015 | 11 | 0.630 |
Why?
|
| Genetic Variation | 10 | 2024 | 1480 | 0.630 |
Why?
|
| Molecular Epidemiology | 2 | 2018 | 156 | 0.600 |
Why?
|
| SEER Program | 6 | 2024 | 194 | 0.600 |
Why?
|
| Risk Assessment | 9 | 2022 | 3316 | 0.590 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 351 | 0.590 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2019 | 214 | 0.580 |
Why?
|
| Sex Characteristics | 1 | 2019 | 313 | 0.570 |
Why?
|
| Gestational Age | 7 | 2023 | 1138 | 0.570 |
Why?
|
| Survival Rate | 10 | 2025 | 1996 | 0.570 |
Why?
|
| Phenotype | 14 | 2024 | 4228 | 0.570 |
Why?
|
| Statistics as Topic | 1 | 2017 | 250 | 0.550 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 21 | 0.550 |
Why?
|
| Hypersensitivity | 2 | 2022 | 182 | 0.540 |
Why?
|
| Germ-Line Mutation | 5 | 2024 | 313 | 0.540 |
Why?
|
| Cohort Studies | 14 | 2024 | 4710 | 0.540 |
Why?
|
| Survivors | 7 | 2022 | 345 | 0.540 |
Why?
|
| Quantitative Trait Loci | 3 | 2022 | 283 | 0.530 |
Why?
|
| Epoxide Hydrolases | 2 | 2013 | 33 | 0.510 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2024 | 178 | 0.510 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 5 | 0.510 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2024 | 130 | 0.510 |
Why?
|
| Tuberous Sclerosis | 3 | 2024 | 121 | 0.510 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 300 | 0.510 |
Why?
|
| Hydrocarbons, Chlorinated | 2 | 2012 | 9 | 0.500 |
Why?
|
| Genetic Testing | 5 | 2024 | 997 | 0.500 |
Why?
|
| Family | 6 | 2023 | 578 | 0.490 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 162 | 0.490 |
Why?
|
| Anencephaly | 3 | 2013 | 11 | 0.490 |
Why?
|
| Smoking | 4 | 2020 | 1031 | 0.480 |
Why?
|
| Parents | 5 | 2024 | 1031 | 0.480 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 237 | 0.480 |
Why?
|
| Syndrome | 5 | 2021 | 1115 | 0.480 |
Why?
|
| CpG Islands | 6 | 2024 | 322 | 0.470 |
Why?
|
| Epigenesis, Genetic | 5 | 2023 | 666 | 0.470 |
Why?
|
| Retrospective Studies | 40 | 2024 | 16033 | 0.460 |
Why?
|
| Prognosis | 15 | 2025 | 4514 | 0.460 |
Why?
|
| Risk | 9 | 2024 | 747 | 0.460 |
Why?
|
| Haplotypes | 2 | 2013 | 519 | 0.450 |
Why?
|
| Transcription Factors | 5 | 2024 | 2585 | 0.450 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2014 | 30 | 0.450 |
Why?
|
| Health Status Disparities | 4 | 2021 | 218 | 0.450 |
Why?
|
| Proteins | 2 | 2019 | 1038 | 0.450 |
Why?
|
| Age Factors | 10 | 2021 | 2802 | 0.450 |
Why?
|
| Environmental Monitoring | 2 | 2015 | 64 | 0.450 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 334 | 0.450 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2013 | 21 | 0.450 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2013 | 220 | 0.440 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 518 | 0.440 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1682 | 0.430 |
Why?
|
| Urticaria | 1 | 2013 | 20 | 0.430 |
Why?
|
| Eczema | 1 | 2013 | 28 | 0.430 |
Why?
|
| Weight Gain | 3 | 2023 | 401 | 0.430 |
Why?
|
| Middle Aged | 22 | 2024 | 26016 | 0.430 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2024 | 48 | 0.430 |
Why?
|
| Cryptosporidium | 2 | 2014 | 32 | 0.420 |
Why?
|
| Intellectual Disability | 4 | 2023 | 1042 | 0.420 |
Why?
|
| GTP Cyclohydrolase | 1 | 2012 | 5 | 0.420 |
Why?
|
| Inhalation Exposure | 2 | 2015 | 36 | 0.420 |
Why?
|
| Pesticides | 3 | 2017 | 20 | 0.410 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 866 | 0.410 |
Why?
|
| Air Pollutants, Occupational | 1 | 2012 | 18 | 0.400 |
Why?
|
| Hypoglycemia | 1 | 2013 | 191 | 0.400 |
Why?
|
| Models, Theoretical | 2 | 2015 | 356 | 0.390 |
Why?
|
| Genetic Association Studies | 7 | 2020 | 761 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1872 | 0.380 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 88 | 0.380 |
Why?
|
| Pregnancy Outcome | 3 | 2021 | 600 | 0.380 |
Why?
|
| Testicular Neoplasms | 2 | 2023 | 132 | 0.370 |
Why?
|
| Genetic Markers | 4 | 2019 | 609 | 0.370 |
Why?
|
| Ebstein Anomaly | 1 | 2011 | 26 | 0.370 |
Why?
|
| Thymidylate Synthase | 1 | 2010 | 22 | 0.370 |
Why?
|
| Vaccination | 1 | 2016 | 950 | 0.360 |
Why?
|
| Fertilization | 2 | 2021 | 43 | 0.360 |
Why?
|
| Paternal Exposure | 3 | 2020 | 10 | 0.350 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2017 | 70 | 0.340 |
Why?
|
| Hernia, Umbilical | 2 | 2020 | 41 | 0.330 |
Why?
|
| Censuses | 2 | 2022 | 11 | 0.330 |
Why?
|
| Body Mass Index | 5 | 2020 | 1541 | 0.330 |
Why?
|
| Insulin Resistance | 1 | 2013 | 638 | 0.310 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5049 | 0.310 |
Why?
|
| Frailty | 2 | 2021 | 98 | 0.300 |
Why?
|
| Cryptosporidiosis | 1 | 2008 | 41 | 0.300 |
Why?
|
| Mutation | 8 | 2025 | 5773 | 0.300 |
Why?
|
| ROC Curve | 4 | 2020 | 557 | 0.300 |
Why?
|
| Dog Diseases | 1 | 2008 | 49 | 0.300 |
Why?
|
| Overweight | 3 | 2022 | 357 | 0.290 |
Why?
|
| Genetic Counseling | 3 | 2024 | 225 | 0.290 |
Why?
|
| Bayes Theorem | 6 | 2023 | 278 | 0.290 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 530 | 0.290 |
Why?
|
| Expert Testimony | 1 | 2007 | 34 | 0.290 |
Why?
|
| Surveys and Questionnaires | 9 | 2023 | 3670 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1232 | 0.290 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2025 | 70 | 0.290 |
Why?
|
| Policy Making | 1 | 2007 | 59 | 0.280 |
Why?
|
| Radiation Exposure | 2 | 2020 | 43 | 0.280 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 594 | 0.270 |
Why?
|
| Holoprosencephaly | 2 | 2021 | 23 | 0.270 |
Why?
|
| Epigenomics | 3 | 2023 | 162 | 0.260 |
Why?
|
| Epilepsy | 3 | 2024 | 858 | 0.260 |
Why?
|
| Dietary Supplements | 4 | 2014 | 472 | 0.260 |
Why?
|
| Asthma | 1 | 2013 | 745 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2025 | 936 | 0.250 |
Why?
|
| Genome, Human | 4 | 2021 | 1268 | 0.250 |
Why?
|
| Portoenterostomy, Hepatic | 3 | 2021 | 49 | 0.250 |
Why?
|
| Zika Virus Infection | 2 | 2018 | 167 | 0.250 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2016 | 50 | 0.250 |
Why?
|
| DiGeorge Syndrome | 2 | 2018 | 79 | 0.250 |
Why?
|
| Leiomyomatosis | 1 | 2025 | 7 | 0.250 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2024 | 29 | 0.240 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.240 |
Why?
|
| DNA Helicases | 2 | 2024 | 224 | 0.240 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.240 |
Why?
|
| Costello Syndrome | 1 | 2024 | 17 | 0.240 |
Why?
|
| Lamin Type A | 1 | 2024 | 10 | 0.240 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.230 |
Why?
|
| Noonan Syndrome | 1 | 2024 | 29 | 0.230 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 96 | 0.230 |
Why?
|
| Comorbidity | 2 | 2019 | 1496 | 0.230 |
Why?
|
| Neurofibromatosis 1 | 1 | 2024 | 60 | 0.230 |
Why?
|
| Infant, Low Birth Weight | 2 | 2023 | 163 | 0.220 |
Why?
|
| Hydroxyurea | 1 | 2024 | 81 | 0.220 |
Why?
|
| Leukemoid Reaction | 1 | 2023 | 3 | 0.220 |
Why?
|
| Constipation | 1 | 2024 | 112 | 0.220 |
Why?
|
| Precision Medicine | 2 | 2025 | 312 | 0.220 |
Why?
|
| Klinefelter Syndrome | 1 | 2023 | 16 | 0.220 |
Why?
|
| Medically Uninsured | 1 | 2024 | 73 | 0.220 |
Why?
|
| Extremities | 1 | 2023 | 82 | 0.220 |
Why?
|
| Research | 2 | 2022 | 263 | 0.220 |
Why?
|
| Urban Population | 3 | 2021 | 221 | 0.220 |
Why?
|
| New York | 2 | 2020 | 68 | 0.210 |
Why?
|
| Salvage Therapy | 1 | 2024 | 193 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2024 | 138 | 0.210 |
Why?
|
| Mediator Complex | 1 | 2023 | 53 | 0.210 |
Why?
|
| Cholangitis | 1 | 2023 | 32 | 0.210 |
Why?
|
| Arkansas | 2 | 2020 | 58 | 0.210 |
Why?
|
| Craniospinal Irradiation | 1 | 2023 | 58 | 0.210 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2014 | 218 | 0.210 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2014 | 164 | 0.210 |
Why?
|
| Social Class | 2 | 2022 | 192 | 0.210 |
Why?
|
| Cardiovascular Abnormalities | 2 | 2019 | 51 | 0.210 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 69 | 0.210 |
Why?
|
| Insurance Coverage | 1 | 2024 | 121 | 0.210 |
Why?
|
| Toluene | 3 | 2013 | 10 | 0.200 |
Why?
|
| Asparaginase | 1 | 2022 | 41 | 0.200 |
Why?
|
| Xylenes | 3 | 2013 | 13 | 0.200 |
Why?
|
| Benzene Derivatives | 3 | 2013 | 19 | 0.200 |
Why?
|
| Prenatal Care | 2 | 2023 | 343 | 0.200 |
Why?
|
| Pyloric Stenosis, Hypertrophic | 1 | 2022 | 6 | 0.200 |
Why?
|
| Solvents | 2 | 2012 | 42 | 0.200 |
Why?
|
| Cognition Disorders | 3 | 2020 | 555 | 0.200 |
Why?
|
| Fetus | 4 | 2022 | 578 | 0.200 |
Why?
|
| Linear Models | 3 | 2017 | 669 | 0.200 |
Why?
|
| Counseling | 1 | 2023 | 219 | 0.200 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 861 | 0.200 |
Why?
|
| Eye Abnormalities | 2 | 2019 | 106 | 0.190 |
Why?
|
| Monocytes | 2 | 2023 | 346 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2023 | 214 | 0.190 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2022 | 48 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2022 | 62 | 0.190 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 5 | 0.190 |
Why?
|
| Tankyrases | 1 | 2021 | 5 | 0.190 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 349 | 0.190 |
Why?
|
| Codon, Nonsense | 2 | 2020 | 131 | 0.190 |
Why?
|
| Carcinoma | 1 | 2024 | 278 | 0.190 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 1661 | 0.190 |
Why?
|
| Frameshift Mutation | 2 | 2020 | 175 | 0.190 |
Why?
|
| Aged | 14 | 2024 | 19098 | 0.190 |
Why?
|
| Cities | 2 | 2014 | 48 | 0.190 |
Why?
|
| Mouth Abnormalities | 1 | 2021 | 15 | 0.190 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.190 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 14 | 0.190 |
Why?
|
| Trisomy 13 Syndrome | 1 | 2021 | 18 | 0.190 |
Why?
|
| Body Size | 1 | 2021 | 53 | 0.190 |
Why?
|
| Teratology | 1 | 2020 | 1 | 0.190 |
Why?
|
| Stress, Psychological | 2 | 2016 | 556 | 0.190 |
Why?
|
| Educational Status | 3 | 2018 | 270 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 105 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 129 | 0.180 |
Why?
|
| Human Growth Hormone | 1 | 2021 | 74 | 0.180 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 33 | 0.180 |
Why?
|
| North Carolina | 1 | 2020 | 58 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2024 | 6040 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2021 | 533 | 0.180 |
Why?
|
| Pregnancy, Multiple | 1 | 2021 | 50 | 0.180 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.180 |
Why?
|
| Biomarkers | 3 | 2021 | 2946 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 352 | 0.180 |
Why?
|
| Forecasting | 1 | 2022 | 354 | 0.180 |
Why?
|
| Massachusetts | 1 | 2020 | 124 | 0.180 |
Why?
|
| Scimitar Syndrome | 1 | 2021 | 52 | 0.180 |
Why?
|
| Limb Deformities, Congenital | 1 | 2021 | 105 | 0.180 |
Why?
|
| Proton Therapy | 1 | 2022 | 123 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 334 | 0.180 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 2020 | 16 | 0.170 |
Why?
|
| HLA Antigens | 2 | 2019 | 243 | 0.170 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 78 | 0.170 |
Why?
|
| Poverty Areas | 2 | 2021 | 30 | 0.170 |
Why?
|
| COUP Transcription Factor I | 1 | 2020 | 91 | 0.170 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 59 | 0.170 |
Why?
|
| Genomics | 4 | 2023 | 1477 | 0.170 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 22 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 225 | 0.170 |
Why?
|
| Membrane Proteins | 3 | 2023 | 1529 | 0.170 |
Why?
|
| Acute Disease | 2 | 2022 | 1093 | 0.170 |
Why?
|
| Computational Biology | 2 | 2021 | 798 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2019 | 9 | 0.170 |
Why?
|
| Telomere-Binding Proteins | 1 | 2020 | 44 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 161 | 0.170 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 54 | 0.170 |
Why?
|
| Models, Genetic | 3 | 2018 | 766 | 0.170 |
Why?
|
| DNA-Binding Proteins | 5 | 2020 | 2048 | 0.170 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6372 | 0.170 |
Why?
|
| Growth Disorders | 1 | 2021 | 207 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 255 | 0.160 |
Why?
|
| Sweden | 1 | 2019 | 34 | 0.160 |
Why?
|
| Pulmonary Veins | 1 | 2021 | 162 | 0.160 |
Why?
|
| Bilirubin | 1 | 2020 | 121 | 0.160 |
Why?
|
| Retinoblastoma | 1 | 2020 | 108 | 0.160 |
Why?
|
| Abdominal Wall | 1 | 2019 | 32 | 0.160 |
Why?
|
| Rural Population | 1 | 2021 | 251 | 0.160 |
Why?
|
| Congresses as Topic | 2 | 2018 | 170 | 0.160 |
Why?
|
| Retinal Neoplasms | 1 | 2020 | 98 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 99 | 0.160 |
Why?
|
| Cisplatin | 2 | 2017 | 242 | 0.160 |
Why?
|
| Housing | 2 | 2018 | 59 | 0.160 |
Why?
|
| Dendritic Cells | 3 | 2023 | 403 | 0.160 |
Why?
|
| Hematopoiesis | 1 | 2021 | 216 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 101 | 0.160 |
Why?
|
| Lactase | 1 | 2019 | 41 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 2 | 2021 | 378 | 0.160 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 73 | 0.160 |
Why?
|
| Metals, Heavy | 1 | 2019 | 18 | 0.160 |
Why?
|
| Seasons | 1 | 2020 | 303 | 0.160 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 614 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 165 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2019 | 106 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2023 | 363 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 227 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 417 | 0.160 |
Why?
|
| Occupational Diseases | 2 | 2016 | 74 | 0.150 |
Why?
|
| Zika Virus | 2 | 2018 | 142 | 0.150 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 3378 | 0.150 |
Why?
|
| Problem Behavior | 1 | 2019 | 37 | 0.150 |
Why?
|
| Histocompatibility | 1 | 2018 | 46 | 0.150 |
Why?
|
| Preconception Care | 2 | 2018 | 19 | 0.150 |
Why?
|
| Data Mining | 1 | 2018 | 54 | 0.150 |
Why?
|
| Celiac Disease | 1 | 2019 | 68 | 0.150 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2018 | 23 | 0.150 |
Why?
|
| Optic Nerve Glioma | 1 | 2018 | 21 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 271 | 0.150 |
Why?
|
| Williams Syndrome | 1 | 2018 | 39 | 0.150 |
Why?
|
| Nervous System Malformations | 1 | 2019 | 127 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2019 | 170 | 0.150 |
Why?
|
| Histocompatibility Testing | 1 | 2018 | 148 | 0.150 |
Why?
|
| Intestinal Atresia | 1 | 2017 | 19 | 0.150 |
Why?
|
| Water Pollution | 1 | 2017 | 1 | 0.150 |
Why?
|
| Smad6 Protein | 1 | 2017 | 8 | 0.150 |
Why?
|
| Drinking Water | 1 | 2017 | 12 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2023 | 12141 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2018 | 178 | 0.140 |
Why?
|
| Language Development Disorders | 1 | 2019 | 173 | 0.140 |
Why?
|
| Prader-Willi Syndrome | 1 | 2018 | 67 | 0.140 |
Why?
|
| Esophageal Atresia | 1 | 2017 | 51 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 207 | 0.140 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2017 | 48 | 0.140 |
Why?
|
| Alleles | 6 | 2021 | 1603 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2017 | 1168 | 0.140 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2018 | 105 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2020 | 3014 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 272 | 0.140 |
Why?
|
| Cytokines | 1 | 2023 | 1285 | 0.140 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 17 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2021 | 1339 | 0.140 |
Why?
|
| Vitamin B 12 | 1 | 2017 | 55 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 286 | 0.140 |
Why?
|
| Amino Acids | 1 | 2019 | 658 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 120 | 0.140 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 607 | 0.140 |
Why?
|
| Melanoma | 1 | 2023 | 824 | 0.140 |
Why?
|
| Europe | 1 | 2017 | 374 | 0.140 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 199 | 0.140 |
Why?
|
| Micronutrients | 1 | 2017 | 67 | 0.130 |
Why?
|
| Mexico | 1 | 2016 | 179 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 396 | 0.130 |
Why?
|
| Health Surveys | 2 | 2018 | 241 | 0.130 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 286 | 0.130 |
Why?
|
| Meningomyelocele | 2 | 2017 | 236 | 0.130 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 40 | 0.130 |
Why?
|
| Ear Diseases | 1 | 2015 | 18 | 0.130 |
Why?
|
| Geography | 1 | 2015 | 112 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 208 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2017 | 343 | 0.130 |
Why?
|
| Thailand | 1 | 2015 | 34 | 0.120 |
Why?
|
| Lymphangioma, Cystic | 1 | 2015 | 16 | 0.120 |
Why?
|
| Lymphangioma | 1 | 2015 | 22 | 0.120 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 139 | 0.120 |
Why?
|
| Colon | 1 | 2017 | 353 | 0.120 |
Why?
|
| Defoliants, Chemical | 1 | 2014 | 1 | 0.120 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2014 | 1 | 0.120 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Workplace | 1 | 2015 | 69 | 0.120 |
Why?
|
| Vietnam Conflict | 1 | 2014 | 9 | 0.120 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2014 | 5 | 0.120 |
Why?
|
| Algorithms | 4 | 2024 | 1593 | 0.120 |
Why?
|
| Seizures | 1 | 2020 | 873 | 0.120 |
Why?
|
| Immunocompetence | 1 | 2014 | 33 | 0.120 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 5 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 372 | 0.120 |
Why?
|
| Birth Order | 1 | 2014 | 7 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 39 | 0.120 |
Why?
|
| Flecainide | 1 | 2014 | 22 | 0.120 |
Why?
|
| Thoracic Neoplasms | 2 | 2024 | 36 | 0.120 |
Why?
|
| Digoxin | 1 | 2014 | 41 | 0.120 |
Why?
|
| DNA | 1 | 2020 | 1592 | 0.120 |
Why?
|
| Astrocytoma | 1 | 2015 | 103 | 0.120 |
Why?
|
| Psychometrics | 2 | 2016 | 657 | 0.110 |
Why?
|
| Age Distribution | 1 | 2015 | 410 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1228 | 0.110 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2013 | 20 | 0.110 |
Why?
|
| Propranolol | 1 | 2014 | 128 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 699 | 0.110 |
Why?
|
| Animals | 9 | 2024 | 33759 | 0.110 |
Why?
|
| Eating | 1 | 2016 | 372 | 0.110 |
Why?
|
| Ependymoma | 1 | 2015 | 134 | 0.110 |
Why?
|
| Baths | 1 | 2013 | 16 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 467 | 0.110 |
Why?
|
| Microcephaly | 1 | 2016 | 328 | 0.110 |
Why?
|
| Swimming Pools | 1 | 2013 | 7 | 0.110 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2014 | 107 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2014 | 123 | 0.110 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2013 | 10 | 0.110 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 337 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 43 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 102 | 0.110 |
Why?
|
| Dementia | 2 | 2008 | 448 | 0.100 |
Why?
|
| Hydrocarbons | 1 | 2012 | 8 | 0.100 |
Why?
|
| Occupations | 1 | 2012 | 21 | 0.100 |
Why?
|
| Disorders of Sex Development | 1 | 2013 | 78 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3274 | 0.100 |
Why?
|
| Endocrine Disruptors | 1 | 2013 | 53 | 0.100 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 153 | 0.100 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2012 | 10 | 0.100 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2012 | 14 | 0.100 |
Why?
|
| Poverty | 1 | 2015 | 419 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 45 | 0.100 |
Why?
|
| Gene Frequency | 3 | 2020 | 713 | 0.100 |
Why?
|
| Neural Tube | 1 | 2012 | 46 | 0.100 |
Why?
|
| Military Personnel | 1 | 2014 | 209 | 0.100 |
Why?
|
| Pregnancy Trimester, First | 1 | 2012 | 111 | 0.100 |
Why?
|
| Gene Expression | 2 | 2017 | 1566 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 1005 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2525 | 0.090 |
Why?
|
| Siblings | 2 | 2024 | 195 | 0.090 |
Why?
|
| Public Health | 2 | 2018 | 261 | 0.090 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2010 | 7 | 0.090 |
Why?
|
| Creatinine | 2 | 2023 | 380 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2014 | 467 | 0.090 |
Why?
|
| Exercise | 1 | 2016 | 808 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 2112 | 0.090 |
Why?
|
| Spine | 2 | 2021 | 143 | 0.090 |
Why?
|
| Cognition | 3 | 2022 | 736 | 0.090 |
Why?
|
| Isoenzymes | 1 | 2010 | 223 | 0.090 |
Why?
|
| Hypertension | 1 | 2018 | 1287 | 0.090 |
Why?
|
| Anus Diseases | 1 | 2009 | 12 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 478 | 0.080 |
Why?
|
| Mutation, Missense | 3 | 2023 | 847 | 0.080 |
Why?
|
| Nodal Protein | 1 | 2009 | 14 | 0.080 |
Why?
|
| Rectal Diseases | 1 | 2009 | 18 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 1584 | 0.080 |
Why?
|
| Glucose | 1 | 2013 | 872 | 0.080 |
Why?
|
| DNA Repair | 1 | 2012 | 579 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2008 | 143 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 28 | 0.070 |
Why?
|
| Environmental Health | 1 | 2007 | 10 | 0.070 |
Why?
|
| Amnesia | 1 | 2007 | 20 | 0.070 |
Why?
|
| Ikaros Transcription Factor | 2 | 2019 | 28 | 0.070 |
Why?
|
| Global Health | 1 | 2012 | 557 | 0.070 |
Why?
|
| Causality | 2 | 2021 | 83 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1386 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1168 | 0.070 |
Why?
|
| DNA Primers | 1 | 2008 | 661 | 0.070 |
Why?
|
| Disease Progression | 4 | 2015 | 2025 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 765 | 0.070 |
Why?
|
| Brain | 2 | 2021 | 2964 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2009 | 305 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1907 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 321 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 1388 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 797 | 0.060 |
Why?
|
| Health Policy | 1 | 2007 | 213 | 0.060 |
Why?
|
| Chromosome Deletion | 2 | 2019 | 638 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 1265 | 0.060 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 22 | 0.060 |
Why?
|
| Software | 2 | 2020 | 678 | 0.060 |
Why?
|
| Liver | 2 | 2023 | 1734 | 0.060 |
Why?
|
| Antisickling Agents | 1 | 2024 | 17 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 1472 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 1423 | 0.060 |
Why?
|
| Splenic Diseases | 1 | 2024 | 28 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2024 | 34 | 0.060 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2024 | 34 | 0.060 |
Why?
|
| Splenectomy | 1 | 2024 | 60 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2016 | 771 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 191 | 0.060 |
Why?
|
| ras Proteins | 1 | 2024 | 136 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 183 | 0.060 |
Why?
|
| Base Sequence | 1 | 2008 | 3091 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2025 | 118 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 56 | 0.050 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2023 | 95 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1591 | 0.050 |
Why?
|
| Neural Crest | 1 | 2023 | 51 | 0.050 |
Why?
|
| Histone Acetyltransferases | 1 | 2024 | 313 | 0.050 |
Why?
|
| Intelligence | 1 | 2023 | 98 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2022 | 28 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2008 | 501 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 581 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 142 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2015 | 740 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 113 | 0.050 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2013 | 80 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2008 | 538 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 43 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 41 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 79 | 0.050 |
Why?
|
| Methylation | 1 | 2022 | 226 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 1260 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 91 | 0.050 |
Why?
|
| Social Adjustment | 1 | 2022 | 85 | 0.050 |
Why?
|
| Choroid | 1 | 2021 | 39 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 239 | 0.050 |
Why?
|
| Time Factors | 3 | 2018 | 6221 | 0.050 |
Why?
|
| Infertility, Male | 1 | 2024 | 262 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2021 | 33 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 149 | 0.050 |
Why?
|
| GATA1 Transcription Factor | 1 | 2021 | 9 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 993 | 0.050 |
Why?
|
| Homozygote | 1 | 2023 | 533 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2022 | 400 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 766 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 217 | 0.050 |
Why?
|
| Information Services | 1 | 2020 | 22 | 0.050 |
Why?
|
| Organizations | 1 | 2020 | 16 | 0.050 |
Why?
|
| Anal Canal | 1 | 2021 | 79 | 0.050 |
Why?
|
| Foot | 1 | 2021 | 63 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 422 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2021 | 423 | 0.050 |
Why?
|
| Cloaca | 1 | 2020 | 15 | 0.050 |
Why?
|
| Genitalia, Male | 1 | 2020 | 37 | 0.050 |
Why?
|
| Anus, Imperforate | 1 | 2020 | 20 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 100 | 0.040 |
Why?
|
| Hand | 1 | 2021 | 102 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2020 | 1014 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 33 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 552 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2023 | 372 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 481 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 39 | 0.040 |
Why?
|
| Trachea | 1 | 2021 | 201 | 0.040 |
Why?
|
| Esophagus | 1 | 2021 | 213 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 672 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 141 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 261 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 191 | 0.040 |
Why?
|
| Introns | 1 | 2020 | 302 | 0.040 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 55 | 0.040 |
Why?
|
| Maternal Inheritance | 1 | 2018 | 13 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 612 | 0.040 |
Why?
|
| Fatigue | 1 | 2020 | 216 | 0.040 |
Why?
|
| Ear | 1 | 2018 | 25 | 0.040 |
Why?
|
| United States Public Health Service | 1 | 2018 | 4 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2019 | 105 | 0.040 |
Why?
|
| Language Development | 1 | 2019 | 32 | 0.040 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 51 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 208 | 0.040 |
Why?
|
| Point Mutation | 1 | 2020 | 348 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 697 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 241 | 0.040 |
Why?
|
| Proteome | 1 | 2020 | 233 | 0.040 |
Why?
|
| Body Composition | 1 | 2021 | 513 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 247 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 186 | 0.040 |
Why?
|
| Retina | 1 | 2021 | 456 | 0.040 |
Why?
|
| Eye Diseases | 1 | 2019 | 113 | 0.040 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2018 | 49 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 173 | 0.040 |
Why?
|
| Penetrance | 1 | 2018 | 103 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 385 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1088 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2018 | 76 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2025 | 796 | 0.040 |
Why?
|
| Water Supply | 1 | 2017 | 25 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 58 | 0.040 |
Why?
|
| Guatemala | 1 | 2017 | 62 | 0.040 |
Why?
|
| Washington | 1 | 2017 | 33 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2019 | 247 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 1863 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 268 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 231 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 577 | 0.040 |
Why?
|
| Chromosome Duplication | 1 | 2018 | 147 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 401 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2017 | 23 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 17503 | 0.030 |
Why?
|
| Arizona | 1 | 2016 | 25 | 0.030 |
Why?
|
| Women, Working | 1 | 2016 | 9 | 0.030 |
Why?
|
| Diet Records | 1 | 2017 | 74 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 72 | 0.030 |
Why?
|
| Ozone | 1 | 2016 | 18 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2020 | 385 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 475 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 373 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 304 | 0.030 |
Why?
|
| Hearing Loss | 1 | 2017 | 131 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 223 | 0.030 |
Why?
|
| Cataract | 1 | 2018 | 218 | 0.030 |
Why?
|
| Minority Groups | 1 | 2018 | 252 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 226 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1877 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 151 | 0.030 |
Why?
|
| Reading | 1 | 2016 | 80 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1401 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 448 | 0.030 |
Why?
|
| Learning | 1 | 2019 | 362 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 60 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 705 | 0.030 |
Why?
|
| Workload | 1 | 2016 | 146 | 0.030 |
Why?
|
| Utah | 1 | 2015 | 45 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 1081 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 685 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 905 | 0.030 |
Why?
|
| Posture | 1 | 2015 | 152 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2009 | 1213 | 0.030 |
Why?
|
| Agent Orange | 1 | 2014 | 3 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 235 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2026 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2015 | 316 | 0.030 |
Why?
|
| History, Ancient | 1 | 2014 | 54 | 0.030 |
Why?
|
| Erdheim-Chester Disease | 1 | 2014 | 23 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 529 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 71 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2008 | 924 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 1337 | 0.030 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2014 | 31 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 2014 | 24 | 0.030 |
Why?
|
| Histiocytosis, Sinus | 1 | 2014 | 31 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2014 | 35 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2014 | 79 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 108 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 69 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 210 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2018 | 444 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 121 | 0.030 |
Why?
|
| Habits | 1 | 2013 | 26 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1476 | 0.030 |
Why?
|
| Income | 1 | 2014 | 133 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 512 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 877 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 279 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Xenobiotics | 1 | 2013 | 27 | 0.030 |
Why?
|
| Betaine | 1 | 2013 | 22 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 788 | 0.030 |
Why?
|
| Acculturation | 1 | 2013 | 68 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 941 | 0.030 |
Why?
|
| Choline | 1 | 2013 | 55 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 315 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 142 | 0.030 |
Why?
|
| Health Behavior | 1 | 2015 | 381 | 0.030 |
Why?
|
| Vitamin B Complex | 1 | 2013 | 41 | 0.030 |
Why?
|
| Vinblastine | 1 | 2012 | 46 | 0.030 |
Why?
|
| Mexican Americans | 1 | 2014 | 204 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 333 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 522 | 0.030 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2012 | 40 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 340 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 274 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2012 | 85 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 770 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 133 | 0.020 |
Why?
|
| Encephalocele | 1 | 2011 | 51 | 0.020 |
Why?
|
| Fetal Death | 1 | 2011 | 113 | 0.020 |
Why?
|
| Pregnant Women | 1 | 2012 | 149 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 4353 | 0.020 |
Why?
|
| Transposition of Great Vessels | 1 | 2012 | 132 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1414 | 0.020 |
Why?
|
| Health Promotion | 1 | 2014 | 390 | 0.020 |
Why?
|
| Pediatrics | 1 | 2019 | 1141 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 2839 | 0.020 |
Why?
|
| Growth Differentiation Factor 1 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Quality of Life | 1 | 2019 | 1929 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 28 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 1198 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2012 | 329 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2009 | 657 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 1001 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 532 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2008 | 89 | 0.020 |
Why?
|
| Medical Records | 1 | 2008 | 190 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 752 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 267 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 455 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1726 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 809 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1239 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2696 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3868 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 4489 | 0.010 |
Why?
|